clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-64-67clinvest-529Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWАлгоритм депрескрайбинга антикоагулянтов у пациентов с COVID-19 после выписки из стационараAnticoagulant deprescribing algorithm in patients with COVID-19 after hospital dischargehttps://orcid.org/0000-0001-7903-2977КрюковА. В.KrykovA. V.

Крюков Александр Викторович – к. м. н., ассистент кафедры онкологии и паллиативной медицины. SPIN-код: 1568-4967

Москва

Kryukov Alexander V. – Candidate of Medical Sciences, assistant of the Department of Oncology and palliative medicine of the Department of Clinical Pharmacology and Therapy. SPIN code: 1568-4967

Moscow

https://orcid.org/0000-0003-0623-7263ОтделеновВ. А.OtdelenovV. A.

Отделенов Виталий Александрович – доцент кафедры клинической фармакологии и терапии. SPIN-код: 8357-5770

Москва

Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770

Moscow

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian Federation20202810202004SФармаCOVID6467Copyright © Крюков А.В., Отделенов В.А., Сычёв Д.А., 20202020Крюков А.В., Отделенов В.А., Сычёв Д.А.Krykov A.V., Otdelenov V.A., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/529

Представлен алгоритм депрескрайбинга антикоагулянтов на амбулаторном этапе у госпитализированных пациентов с COVID-19. Целесообразно продолжить применение антикоагулянтов при наличии показаний к лечебным дозам антикоагулянтов. Для пациентов с высоким риском венозных тромбоэмболических осложнений (ВТЭО) при низком риске кровотечений целесообразно рассмотреть возможность расширенной профилактики ВТЭО на амбулаторном этапе.

We present anticoagulant outpatient deprescribing algorithm in patients with COVID-19 discharged from the hospital. It is reasonable to continue the treatment should the patient have indications for therapeutic anticoagulation. Enhanced prophylaxis of venous thromboembolic complications should be considered in patients with high thromboembolic risk and low risk of bleeding.

коронавирусалгоритм депрескрайбинга антикоагулянтовCOVID-19coronavirusanticoagulant deprescribing algorithmCOVID-19ReferencesSpyropoulos AC et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. DOI: 10.1378/chest.10-1944Spyropoulos AC et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. DOI: 10.1378/chest.10-1944Amin AN et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012 Mar;7(3):231-8. DOI: 10.1002/jhm.1002Amin AN et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012 Mar;7(3):231-8. DOI: 10.1002/jhm.1002Cohoon KP et al. Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study. Am J Med. 2018 Mar;131(3):307-316.e2. DOI: 10.1016/j.amjmed.2017.09.015Cohoon KP et al. Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study. Am J Med. 2018 Mar;131(3):307-316.e2. DOI: 10.1016/j.amjmed.2017.09.015Smeeth L et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006 Apr 1;367(9516):1075-1079. DOI: 10.1016/S0140-6736(06)68474-2Smeeth L et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006 Apr 1;367(9516):1075-1079. DOI: 10.1016/S0140-6736(06)68474-2Schmidt M et al. Acute infections and venous thromboembolism. J Intern Med. 2012 Jun;271(6):608-18. DOI: 10.1111/j.1365-2796.2011.02473Schmidt M et al. Acute infections and venous thromboembolism. J Intern Med. 2012 Jun;271(6):608-18. DOI: 10.1111/j.1365-2796.2011.02473Konstantinides SV et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. DOI: 10.1093/eurheartj/ehz405Konstantinides SV et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. DOI: 10.1093/eurheartj/ehz405Wang L, Sengupta N, Baser O. Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge. Thromb J. 2011 Oct 13;9(1):15. DOI: 10.1186/1477-9560-9-15Wang L, Sengupta N, Baser O. Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge. Thromb J. 2011 Oct 13;9(1):15. DOI: 10.1186/1477-9560-9-15Kahn SR et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-e226S. DOI: 10.1378/chest.11-2296Kahn SR et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-e226S. DOI: 10.1378/chest.11-2296Spyropoulos AC et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open. 2020 Mar 13;4(1):e59-e65. DOI: 10.1055/s-0040-1705137Spyropoulos AC et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open. 2020 Mar 13;4(1):e59-e65. DOI: 10.1055/s-0040-1705137Cohen AT et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 Aug 11;375(6):534-44. DOI: 10.1056/NEJMoa1601747Cohen AT et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 Aug 11;375(6):534-44. DOI: 10.1056/NEJMoa1601747Cohoon KP et al. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. J Thromb Haemost. 2018 Jul;16(7):1278-1287. DOI: 10.1111/jth.14146.Cohoon KP et al. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. J Thromb Haemost. 2018 Jul;16(7):1278-1287. DOI: 10.1111/jth.14146.Hull RD et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility: A Randomized Trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. DOI: 10.7326/00034819-153-1-201007060-00004Hull RD et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility: A Randomized Trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. DOI: 10.7326/00034819-153-1-201007060-00004Cohen AT et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. DOI: 10.1056/NEJMoa1111096Cohen AT et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. DOI: 10.1056/NEJMoa1111096Spyropoulos AC, Ageno W, Albers GW et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. DOI: 10.1056/NEJMoa1805090Spyropoulos AC, Ageno W, Albers GW et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. DOI: 10.1056/NEJMoa1805090Brighton and Sussex University Hospitals. Guidance on Thromboprophylaxis, Thrombosis and Coagulopathy Management in COVID-19 [Internet]. 2020. P. 1—13. [cited 2020 May 29]; Available from: https://www.bsuh.nhs.uk/library/wp-content/uploads/sites/8/2020/05/Covid169_Final-BSUH-COVID-Thromboprophylaxis-Thrombosis-andCoagulopathy-Guidance-v-1.1-6.pdfBrighton and Sussex University Hospitals. Guidance on Thromboprophylaxis, Thrombosis and Coagulopathy Management in COVID-19 [Internet]. 2020. P. 1—13. [cited 2020 May 29]; Available from: https://www.bsuh.nhs.uk/library/wp-content/uploads/sites/8/2020/05/Covid169_Final-BSUH-COVID-Thromboprophylaxis-Thrombosis-andCoagulopathy-Guidance-v-1.1-6.pdf

The authors declare that there are no conflicts of interest present.